A Single Arm, Open Label, Multicenter, Extended Treatment, Safety Study in Patients Treated With Talazoparib
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2017
At a glance
- Drugs Talazoparib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Medivation; Pfizer
- 01 Aug 2017 Planned primary completion date changed from 1 Dec 2020 to 30 Jun 2020.
- 31 Jan 2017 Status changed from not yet recruiting to recruiting.
- 13 Sep 2016 New trial record